PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

PharmaShots Weekly Snapshots (January 17 - 21, 2022)

PharmaShots Weekly Snapshots (January 17 - 21, 2022)

January 21, 2022

BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

January 21, 2022

ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis

ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis

January 21, 2022

Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus

Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus

January 21, 2022

Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC

Turning Point Reports the US FDA’s IND Clearance of Elzovantinib + Aumolertinib for EGFR Mutant Met-Amplified NSCLC

January 21, 2022

Merck and Eisai Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III (KEYNOTE-775/Study 309) Trial for Advanced EC

Merck and Eisai Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III (KEYNOTE-775/Study 309) Trial for Adv...

January 21, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us